Pancreatic enzyme supplementation in pancreatic cancer

Journal of Supportive Oncology

Volumn 6, Issue 8, 2008, Pages 393-396

  Damerla, Venugopal ^a   Gotlieb, Vladimir ^b   Larson, Heidi ^c   Saif, Muhammad Wasif ^d,e,f  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROOKLYN HOSPITAL CENTER   (United States)

^c YALE CANCER CENTER   (United States)

^d Gastrointestinal Malignancies Program   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Division of Medical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; ANTINEOPLASTIC AGENT; CALCIUM; CHYMOTRYPSIN; CYANOCOBALAMIN; DIGESTIVE TRACT AGENT; IRON; KREON; KU ZYME; MICROSPHERE; MINERAL; MULTIVITAMIN; PANCREAS ENZYME; PANCREATIN; PANCREATIN KUTRASE; PANCRELIPASE; PLACEBO; PROTEINASE; PROTON PUMP INHIBITOR; TRIACYLGLYCEROL LIPASE; TRYPSIN; UNCLASSIFIED DRUG; ZINC;

ARTICLE; CALORIC INTAKE; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DIET SUPPLEMENTATION; DRUG COST; DRUG DOSE ESCALATION; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERIC COATED TABLET; ENZYME RELEASE; GASTROINTESTINAL SYMPTOM; HUMAN; IRON DEFICIENCY ANEMIA; MALABSORPTION; NUTRITIONAL COUNSELING; NUTRITIONAL SUPPORT; PANCREAS CANCER; PANCREAS EXOCRINE INSUFFICIENCY; PANCREATICODUODENECTOMY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; TREATMENT INDICATION; VITAMIN SUPPLEMENTATION; PANCREAS TUMOR;

HUMANS; NUTRITIONAL SUPPORT; PANCREATIC NEOPLASMS; PANCREATIN; PRACTICE GUIDELINES AS TOPIC;

EID: 59449104012     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Ihse I, Arnesjö B, Kugelberg C, Lilja P. Intestinal activities of trypsin, lipase, and phospholipase after a test meal: an evaluation of 474 examinations. Scand J Gastroenterol 1977;12:663-668.
3. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 1988;148:1586-1591.
4. Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut 2005;54(suppl 6):vi1-vi28.
5. DiMagno EP, Malagelada JR, Go VL. The relationships between pancreatic ductal obstruction and pancreatic secretion in man. Mayo Clin Proc 1979;54:157-162.
6. Michelassi F, Erroi F, Dawson PJ, et al. Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct. Ann Surg 1989;210:544-556.
7. Perez MM, Newcomer AD, Moertel CG, Go VL, DiMagno EP. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer 1983;52:346-352.
8. Matsumoto J, Traverso LW. Exocrine function following the whipple operation assessed by stool elastase. J Gastrointest Surg 2006;10:1225-1229.
9. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491-497.
10. Capuano G, Grosso A, Gentile PC, et al. Influence of weight loss on outcomes in patients with head and neck cancer undergoing concomitant chemoradiotherapy. Head Neck 2008;30:503-508.
11. Fearon KC, Voss AC, Hustead DS; Cancer Cachexia Study Group. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006;83:1345-1350.
12. Gullo L, Barbara L, Labò G. Effect of cessation of alcohol use on the course of pancreatic dysfunction in alcoholic pancreatitis. Gastroenterology 1988;95:1063-1068.
13. Anderson JJB. Minerals. In: Mahan LK, Escott-Stump S, eds. Krauses's Food Nutrition and Diet Therapy. 11th ed. Philadelphia: WB Saunders; 2003:120-163.
14. Bank S. Chronic pancreatitis: clinical features and medical management. Am J Gastroenterol 1986;81:153-167.
15. Domínguez-Muñoz JE, Iglesias-Garcia J, Vilariño-Insua M, Iglesias-Rey M. 13C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2007;5:484-488.
16. Dominguez-Munoz JE. Management of maldigestion in chronic pancreatitis: a practical protocol. In: Dominguez-Munoz JE, ed. Clinical Pancreatology for Practicing Gastroenterologists and Surgeons. London: Blackwell Publishing; 2005:288-295.
17. DiMagno EP, Malagelada JR, Go VL, Moertel CG. Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two dosage schedules. N Engl J Med 1977;296:1318-1322.
18. Bruno MJ, Haverkort EB, Tijssen GP, Tytgat GN, van Leeuwen DJ. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 1998;42:92-96.
19. Kühnelt P, Mundlos S, Adler G. Effect of pellet size of a pancreas enzyme preparation on duodenal lipolytic activity [in German]. Z Gastroenterol 1991;29:417-421.
20. Safdi M, Bekal PK, Martin S, Saeed ZA, Burton F, Toskes PP. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas 2006;33:156-162.
21. Domínguez-Muñoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep 2007;9:116-122.
22. Ottery F. Supportive nutritional management of the patient with pancreatic cancer. Oncology (Williston Park) 1996;10(9 suppl):26-32.
23. Brady MS, Garson JL, Krug SK, et al. 23. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study. J Am Diet Assoc 2006;106:1181-1186.